Edwards Lifesciences Corporation (EW) Stock

NYSE
HealthcareMedical Devices Website

EW has an Alpha Score of 46 out of 100 (weak), computed on Nov 12, 2026 from 3 of 4 sub-scores. 16 members of Congress disclosed 30 trades in EW since 2014: 14 purchases and 16 sales, most recently Alan Armstrong (purchase, Mar 27, 2026). 6 of the hedge funds AlphaScala tracks reported EW in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Citadel's at $361.65M. Company insiders reported 0 open-market buys and 11 sales on SEC Form 4 in the 90 days to Nov 13, 2026. Its trailing P/E ratio is 57.8 and its net margin 15.3% (key statistics as of Nov 11, 2026).

$107.11
-0.04%
Last price
Source: Finnhub
Alpha Score
46
Weak

What is EW's Alpha Score?

How it works →

Alpha Score of 46 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
92
Strong
Value
3
Poor
Quality
51
Weak

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 12, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Edwards Lifesciences Corporation (EW)?

Members
16
Disclosed trades
30
Purchases
14
Sales
16

Most recent: Alan Armstrong (purchase, Mar 27, 2026); records start Feb 14, 2014.

PoliticianTrade dateTypeAmount
Alan Armstrong
R-OK · Senate
2026-03-27purchase$1k – $15k
Josh Gottheimer
D-NJ · House
2025-11-19sale$1k – $15k
Jefferson Shreve
R-IN · House
2025-05-12sale$50k – $100k
Bruce Westerman
R-AR · House
2025-04-21sale$1k – $15k
Rob Bresnahan
R-PA · House
2025-04-08purchase$1k – $15k
Jefferson Shreve
R-IN · House
2025-04-07purchase$15k – $50k
Bruce Westerman
R-AR · House
2025-03-03purchase$1k – $15k
Markwayne Mullin
R-OK · Senate
2024-08-20partial sale$15k – $50k

From STOCK Act periodic transaction reports. House filings as of Nov 13, 2026. Senate records here end Nov 4, 2026; later Senate trades are not included.

See all EW political trades →

Which hedge funds own EW?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Citadel
Ken Griffin
4.00M$361.65M+670%
Millennium Management
Israel Englander
3.58M$324.28M+100%
Point72
Steve Cohen
1.77M$160.49M-3%
Bridgewater Associates
Ray Dalio
275K$24.90M+60%
Renaissance Technologies
Jim Simons (founder)
105K$9.05M+400%
Marshall Wace80K$6.91M-77%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Edwards Lifesciences Corporation insiders buying or selling?

SEC Form 4 filings
90 days to Nov 13, 2026
Buys
0
Sells
11
Net $
-$10.9M
Unique insiders
7
DateInsiderRoleTypeSharesValue
Nov 10, 26Lippis Daniel J.CVP, TAVRSELL619$65K
Nov 9, 26Bobo Donald E JrCVP,Strategy/Corp DevelopmentSELL48.9K$5.0M
Nov 9, 26Zovighian Bernard JCEOSELL9.2K$949K
Nov 9, 26Zovighian Bernard JCEOSELL13.9K$1.4M
Oct 8, 26Lippis Daniel J.CVP, TAVRSELL619$53K
Sep 11, 26Lippis Daniel J.CVP, TAVRSELL619$54K
Aug 31, 26Dahl Andrew M.SVP, Corporate ControllerSELL544$50K
Aug 28, 26Bruls AnnetteCVP, EMEACLASELL2.6K$238K
Aug 26, 26Markowitz WayneCVP, JAPACSELL1.2K$113K
Aug 26, 26Chopra DaveenCVP, TMTT, Surgical & IHFMSELL1.2K$106K

SEC Form 4 filings as of Nov 13, 2026 · not updated for 4 days; newer filings may exist

See cluster-buy signals across all tickers →

What are EW's key statistics?

P/E Ratio
57.81
EPS (TTM)
1.76
Beta
0.75
Net Margin
15.30%
ROE
9.69%
Debt / Equity
0.06
52W High
$105.37
52W Low
$74.66

Key statistics as of Nov 11, 2026

How does EW's valuation compare with the Healthcare sector?

MetricEWHealthcare medianCompanies in median
P/E ratio57.827.3136
Net margin15.30%3.60%205
Return on equity9.69%4.11%232

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 17, 2026). P/E excludes loss-making companies.

EW price chart

Powered by TradingView

What does Edwards Lifesciences Corporation do?

Edwards Lifesciences Corporation is the leading global structural heart innovation company, specializing in patient-focused medical devices for structural heart disease, critical care, and surgical monitoring. The company develops and commercializes breakthrough technologies, including pioneering transcatheter aortic valve replacement (TAVR) systems and hemodynamic monitoring solutions, to address unmet needs in cardiovascular care through minimally invasive procedures. Its product portfolio encompasses heart valve therapies and monitoring systems that enhance patient outcomes and quality of life. Edwards Lifesciences Corporation collaborates with leading clinicians and researchers worldwide to deliver innovations in structural heart procedures, such as TAVR and mitral platforms, alongside critical care technologies. These offerings serve healthcare providers globally, emphasizing structural heart disease management and procedural efficiency. Founded in 2000 and headquartered in Irvine, California, Edwards Lifesciences Corporation plays a pivotal role in the medical device industry by advancing cardiovascular solutions and supporting clinical advancements in heart care.

CEO
Mr. Bernard J. Zovighian
Employees
16,000
Market Cap
$59.04B
Ask about EWAI research agent